Affiliation: Stony Brook University
- Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysisXiaolei Zhu
Division of Nephrology, SUNY at Stony Brook, NY, USA
Am J Kidney Dis 49:186-93. 2007..We performed a systematic review and meta-analysis of published clinical trials of bevacizumab to quantify the risk of proteinuria and hypertension...
- Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysisShenhong Wu
Division of Medical Oncology, Department of Medicine, State University of New York, Stony Brook, NY 11794 9447, USA
Lancet Oncol 9:117-23. 2008..The aim of this study is to gain a better understanding of the overall risk of hypertension in patients with cancer who receive sorafenib...
- Bevacizumab increases risk for severe proteinuria in cancer patientsShenhong Wu
Division of Hematology and Oncology, Stony Brook University Medical Center, Stony Brook, New York, USA
J Am Soc Nephrol 21:1381-9. 2010..39). In conclusion, the addition of bevacizumab to chemotherapy significantly increases the risk for high-grade proteinuria and nephrotic syndrome...
- Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysisXiaolei Zhu
Kidney Specialists of Long Island, Port Jefferson Station, NY, USA
Acta Oncol 48:9-17. 2009..We here performed a systematic review and meta-analysis of published clinical trials to determine its overall risk...